Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Adoptive Regulatory T Cell Therapy in a Patient with Systemic Lupus Erythematosus.

Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandoval PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD; Autoimmunity Centers of Excellence.

Arthritis Rheumatol. 2018 Oct 1. doi: 10.1002/art.40737. [Epub ahead of print]

PMID:
30277008
2.

Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus Nephritis.

Shidham G, Ayoub I, Birmingham D, Hebert P, Rovin B, Diamond B, Wofsy D, Hebert L.

Kidney Int Rep. 2018 Apr 27;3(5):1057-1063. doi: 10.1016/j.ekir.2018.04.010. eCollection 2018 Sep.

3.

Do Admissions Multiple Mini-Interview and Traditional Interview Scores Predict Subsequent Academic Performance? A Study of Five California Medical Schools.

Jerant A, Henderson MC, Griffin E, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Tancredi DJ, Sousa FJ, Franks P.

Acad Med. 2018 Sep 4. doi: 10.1097/ACM.0000000000002440. [Epub ahead of print]

PMID:
30188370
4.

Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.

Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS.

Ann Rheum Dis. 2018 Jun;77(6):883-889. doi: 10.1136/annrheumdis-2018-213032. Epub 2018 Mar 21.

5.

Do Multiple Mini-Interview and Traditional Interview Scores Differ in Their Associations With Acceptance Offers Within and Across Five California Medical Schools?

Jerant A, Henderson MC, Griffin E, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P.

Acad Med. 2018 Aug;93(8):1227-1233. doi: 10.1097/ACM.0000000000002223.

6.

Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis.

Smilek DE, Lim N, Ding L, Murray SG, Diamond B, Wofsy D.

Lupus Sci Med. 2017 Aug 31;4(1):e000229. doi: 10.1136/lupus-2017-000229. eCollection 2017.

7.

Reliability of Multiple Mini-Interviews and traditional interviews within and between institutions: a study of five California medical schools.

Jerant A, Henderson MC, Griffin E, Rainwater JA, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P.

BMC Med Educ. 2017 Nov 6;17(1):190. doi: 10.1186/s12909-017-1030-0.

8.

Medical School Applicant Characteristics Associated With Performance in Multiple Mini-Interviews Versus Traditional Interviews: A Multi-Institutional Study.

Henderson MC, Kelly CJ, Griffin E, Hall TR, Jerant A, Peterson EM, Rainwater JA, Sousa FJ, Wofsy D, Franks P.

Acad Med. 2018 Jul;93(7):1029-1034. doi: 10.1097/ACM.0000000000002041.

PMID:
29095170
9.

Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration.

Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne D, Kamen D, Lerstrøm K, Mosca M, Ramsey-Goldman R, Sinnette C, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH.

Arthritis Care Res (Hoboken). 2018 Apr;70(4):571-581. doi: 10.1002/acr.23317. Epub 2018 Feb 22.

10.

Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.

Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D.

Arthritis Rheumatol. 2017 Jan;69(1):122-130. doi: 10.1002/art.39809. Epub 2016 Dec 2.

11.

In memoriam: Ephraim P. Engleman, MD, 1911-2015.

Wofsy D.

Arthritis Rheumatol. 2015 Nov;67(11):2795-6. doi: 10.1002/art.39440. No abstract available.

12.

Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome.

Dall'Era M, Levesque V, Solomons N, Truman M, Wofsy D.

Lupus Sci Med. 2015 May 20;2(1):e000089. doi: 10.1136/lupus-2015-000089. eCollection 2015.

13.

Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America.

Wofsy D, Diamond B, Houssiau FA.

Arthritis Rheumatol. 2015 May;67(5):1144-6. doi: 10.1002/art.39067. No abstract available.

14.

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D.

Ann Rheum Dis. 2015 Nov;74(11):2006-15. doi: 10.1136/annrheumdis-2013-205067. Epub 2014 Jun 20. Erratum in: Ann Rheum Dis. 2016 May;75(5):946.

15.

Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials.

Wofsy D, Hillson JL, Diamond B.

Arthritis Rheum. 2013 Jun;65(6):1586-91. doi: 10.1002/art.37940.

16.

Recent progress in conventional and biologic therapy for systemic lupus erythematosus.

Wofsy D.

Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii66-8. doi: 10.1136/annrheumdis-2012-202204. Epub 2012 Dec 19. Review.

PMID:
23253930
17.

Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions.

Wofsy D, Hillson JL, Diamond B.

Arthritis Rheum. 2012 Nov;64(11):3660-5. doi: 10.1002/art.34624.

18.

Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group.

N Engl J Med. 2011 Nov 17;365(20):1886-95. doi: 10.1056/NEJMoa1014460.

19.

A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis.

Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE.

J Rheumatol. 2011 May;38(5):846-54. doi: 10.3899/jrheum.100602. Epub 2011 Feb 1.

PMID:
21285160
20.

Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.

Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D.

Arthritis Care Res (Hoboken). 2011 Mar;63(3):351-7. doi: 10.1002/acr.20397. Epub 2010 Nov 15.

21.

Plagiarism on personal statements: a disturbing symptom of a broader trend.

Papadakis MA, Wofsy D.

Ann Intern Med. 2010 Jul 20;153(2):128-9. doi: 10.7326/0003-4819-153-2-201007200-00010. No abstract available.

PMID:
20643994
22.

Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through?

Dall'Era M, Wofsy D.

Nat Rev Rheumatol. 2010 Mar;6(3):124-5. doi: 10.1038/nrrheum.2010.20. No abstract available.

PMID:
20197774
23.

Biologic therapy for systemic lupus erythematosus.

Dall'Era M, Wofsy D.

Discov Med. 2010 Jan;9(44):20-3. Review.

24.

Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.

Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA; ALMS Group.

Arthritis Rheum. 2010 Jan;62(1):211-21. doi: 10.1002/art.25052. Erratum in: Arthritis Rheum. 2010 Oct;62(10):3005.

25.

Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study.

Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sánchez-Guerrero J, Wofsy D, Yu X, Solomons N.

Rheumatology (Oxford). 2010 Jan;49(1):128-40. doi: 10.1093/rheumatology/kep346. Epub 2009 Nov 20.

26.

Regulatory T cells as therapeutic targets in rheumatoid arthritis.

Esensten JH, Wofsy D, Bluestone JA.

Nat Rev Rheumatol. 2009 Oct;5(10):560-5. doi: 10.1038/nrrheum.2009.183. Review.

27.

Systemic lupus erythematosus clinical trials-an interim analysis.

Dall'Era M, Wofsy D.

Nat Rev Rheumatol. 2009 Jun;5(6):348-51. doi: 10.1038/nrrheum.2009.79. Review.

PMID:
19491915
28.

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group.

J Am Soc Nephrol. 2009 May;20(5):1103-12. doi: 10.1681/ASN.2008101028. Epub 2009 Apr 15.

29.

Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest.

Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH Jr, Thomson GE, Wofsy D.

JAMA. 2009 Apr 1;301(13):1367-72. doi: 10.1001/jama.2009.407.

PMID:
19336712
30.

A quality indicator set for systemic lupus erythematosus.

Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, Yelin E; Systemic Lupus Erythematosus Quality Indicators Project Expert Panels.

Arthritis Rheum. 2009 Mar 15;61(3):370-7. doi: 10.1002/art.24356.

31.

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.

Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D.

Arthritis Rheum. 2007 Dec;56(12):4142-50.

32.

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).

Sinclair A, Appel G, Dooley MA, Ginzler E, Isenberg D, Jayne D, Wofsy D, Solomons N.

Lupus. 2007;16(12):972-80.

PMID:
18042591
33.

Clinical trial design in systemic lupus erythematosus.

Dall'Era M, Wofsy D.

Curr Opin Rheumatol. 2006 Sep;18(5):476-80. Review.

PMID:
16896285
34.

Inhibition of T cell costimulation: an emerging therapeutic strategy for autoimmune rheumatic diseases.

Daikh DI, Gillis J, Wofsy D.

Arthritis Rheum. 2006 Apr 15;55(2):322-4. No abstract available.

35.

Block and tackle: CTLA4Ig takes on lupus.

Davidson A, Diamond B, Wofsy D, Daikh D.

Lupus. 2005;14(3):197-203. Review.

PMID:
15807196
36.

Living in a different world.

Wofsy D.

Arthritis Rheum. 2005 Feb;52(2):395-401. No abstract available.

37.

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.

Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D; IDEC-131 Lupus Study Group.

Arthritis Rheum. 2002 Dec;46(12):3251-8.

38.

Treatment of autoimmune diseases by inhibition of T-cell costimulation.

Wofsy D, Daikh DI.

Mod Rheumatol. 2002 Mar;12(1):1-4. doi: 10.3109/s101650200000.

PMID:
24383824
39.

The immune tolerance network and rheumatic disease: immune tolerance comes to the clinic.

Diamond B, Bluestone J, Wofsy D.

Arthritis Rheum. 2001 Aug;44(8):1730-5. Review.

40.

Treatment of autoimmunity by inhibition of T cell costimulation.

Daikh DI, Wofsy D.

Adv Exp Med Biol. 2001;490:113-7. Review. No abstract available.

PMID:
11505969
41.

Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.

Davis JC Jr, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D.

J Rheumatol. 2001 Jan;28(1):95-101.

PMID:
11196549
42.
43.

Nephritogenic cytokines and disease in MRL-Fas(lpr) kidneys are dependent on multiple T-cell subsets.

Wada T, Schwarting A, Chesnutt MS, Wofsy D, Rubin Kelley V.

Kidney Int. 2001 Feb;59(2):565-78.

44.

The effect on immunoglobulin glycosylation of altering in vivo production of immunoglobulin G.

Jeddi P, Keusch J, Lydyard PM, Bodman-Smith KB, Chesnutt MS, Wofsy D, Hirota H, Taga T, Delves PJ.

Immunology. 1999 Nov;98(3):475-80.

45.

Effects of anti-B7 monoclonal antibodies on humoral immune responses.

Daikh DI, Wofsy D.

J Autoimmun. 1999 Mar;12(2):101-8.

PMID:
10047430
46.

Opportunities for future biological therapy in SLE.

Wofsy D, Daikh DI.

Baillieres Clin Rheumatol. 1998 Aug;12(3):529-41. Review.

PMID:
9890111
47.

On the horizon: clinical trials of new immunosuppressive strategies for autoimmune diseases.

Daikh DI, Wofsy D.

Transplant Proc. 1998 Dec;30(8):4027-8. Review. No abstract available.

PMID:
9865285
48.

Enhanced lymphoproliferation and diminished autoimmunity in CD4-deficient MRL/lpr mice.

Chesnutt MS, Finck BK, Killeen N, Connolly MK, Goodman H, Wofsy D.

Clin Immunol Immunopathol. 1998 Apr;87(1):23-32.

PMID:
9576007
49.

Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways.

Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D.

J Immunol. 1997 Oct 1;159(7):3104-8.

PMID:
9317105
50.

The CD28-B7 costimulatory pathway and its role in autoimmune disease.

Daikh D, Wofsy D, Imboden JB.

J Leukoc Biol. 1997 Aug;62(2):156-62. Review.

PMID:
9261329

Supplemental Content

Support Center